1
|
Abstract
Aberrant mutations of centrocytes in germinal centers (GC) can generate two completely different diseases: B-cell lymphomas and monoclonal gammopathy of undetermined significance (MGUS). In this article we use computational models to examine the evolutionary dynamics by which initial adaptation to survival in the GC allows naive MGUS cells to proliferate in the bone marrow and initiate the evolutionary process that will lead to aggressive multiple myeloma (MM). Our simulations show that MGUS cells may generate bone marrow tumors ranging from indolent to aggressive, depending on the original adaptation in the GC. All these tumors, however, are limited to approximately 15% of the marrow cellularity due to hypoxia-induced quiescence (this correlates with the cellularity that separates MGUS and MM, ∼10%). Resistance to hypoxia-induced quiescence and cell death was one of the two major bone marrow adaptations that allowed continued tumor growth and establishment of paracrine cytokine loops, known to increase MM cell replication and de novo multidrug resistance. The second major adaptation was an increase in IL-6-independent growth rate, which correlates with the mutations observed in advanced stage patients. Even though there was an increase in the microvessel density in all simulations, the "angiogenic switch" was not due to a MM angiogenic phenotype, but rather the response of MM cells to the regional hypoxia caused by the increased tumor burden. These results indicate that treatments targeting the adaptation to survival and proliferation in hypoxia, in conjunction with currently available therapies, may have synergistic effects, by delaying tumor growth and reducing cytokine paracrine loops mediated by angiogenic factors.
Collapse
Affiliation(s)
- Ariosto S Silva
- Department of Cancer Imaging Research, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States
| | | |
Collapse
|
2
|
Várkonyi J, Bajzik E, Fazakas A, Sipka S, Karádi I. Short or long survival in multiple myeloma. A simple method for determining the prognosis. Pathol Oncol Res 2008; 15:383-7. [PMID: 19052918 DOI: 10.1007/s12253-008-9134-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2008] [Accepted: 11/20/2008] [Indexed: 12/22/2022]
Abstract
Finding prognostic factors in multiple myeloma is a real challenge. Several attempts might be found in the literature for that purpose but the results are not satisfactory. Therefore, in the current retorpective study authors analyzed the potential prognostic value of some laboratory data in 104 patients with multiple myeloma. They found the albumin and M-component ratio being lower than 1 and the initial WBC <4,5 x 10(9)/l correlated strongly with poor prognosis. In addition the low albumin level was not related to albuminuria and that the low WBC was not linked to bone marrow infiltration rate or to antineutrophil antibody formation. On the basis of their experiences authors created an AMWBC score containing A/M and WBC at diagnosis found to be in good correlation to prognosis. Further studies involving more patients are needed to verify the real prognostic value of AMWBC score in multiple myeloma treated with new targeted therapies.
Collapse
Affiliation(s)
- Judit Várkonyi
- 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4., 1125 Budapest, Hungary.
| | | | | | | | | |
Collapse
|
3
|
Cascio P, Oliva L, Cerruti F, Mariani E, Pasqualetto E, Cenci S, Sitia R. Dampening Ab responses using proteasome inhibitors followingin vivo B cell activation. Eur J Immunol 2008; 38:658-67. [DOI: 10.1002/eji.200737743] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
4
|
Abstract
Like us, our cells have evolved strategies to cope with, and sometimes utilize, stress. Molecular analyses of plasma cell biogenesis, lifestyle and death suggest that protein synthesis-dependent stress is utilised to integrate differentiation, function and lifespan control. Plasma cells are short-lived professional secretory cells, each of them capable of releasing several thousands antibodies per second. Their differentiation from B lymphocytes entails the spectacular enlargement of the endoplasmic reticulum (ER), finalized to sustain massive Ig production. Nonetheless, symptoms of ER stress are evident, and the UPR-related transcription factor XBP-1 is essential for differentiation. Surprisingly, the development of such an efficient factory is matched by a decrease in proteasomes. The unbalanced load/capacity ratio leads to accumulation of polyubiquitinated molecules and predisposes plasma cells to apoptosis. Exuberant antibody secretion imposes considerable stress on metabolic and redox homeostasis. Collectively, these stressful conditions may link plasma cell death to antibody production, providing a molecular counter for secreted molecules, as well as an explanation for the peculiar sensitivity of myeloma cells towards proteasome inhibitors.
Collapse
Affiliation(s)
- Simone Cenci
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Universitá Vita-Salute San Raffaele, Milan, Italy
| | | |
Collapse
|
5
|
Abstract
OBJECTIVE Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden. This approach has not been studied in gliomas. METHODS Methylation specific polymerase chain reaction (MSP) was used to determine the methylation status the promoters for p16/(INK4a), MGMT, p73, and RARbeta within glioma tissue and plasma. Blood was collected prior to craniotomy in 10 patients with glioma. DNA was extracted from tumor and plasma samples and assayed with MSP. Total plasma DNA also was quantified. Tumor-specific plasma DNA was defined as identification of the same methylated promoter (MP) in both tumor and plasma. RESULTS Total plasma DNA concentration was markedly elevated (mean 6,503 ng/ml, SEM 1,400 ng/ml). Glioma tissue contained methylation of at least one promoter in 9 out of 10 (90 percent) of patients studied. Of these patients, 6 out of 9 (67 percent) demonstrated methylation of at least one of the same promoters in plasma. Five of these had one MP identified in the plasma and one had 2 MP. Overall, glioma-specific plasma DNA was present in plasma of 6 out of 10 (60 percent) of patients. Each MP DNA marker found in the plasma also was present in the intracranial tumor. CONCLUSIONS Patients with high grade gliomas have large amounts of DNA in the plasma. Of these primary brain tumors, 90 percent contained methylated gene promoters, and in over 60 percent of these patients the same methylated promoters present in the tumor also were found in the plasma. This represents the first step to developing a quantitative plasma biomarker that could be used to monitor glioma status.
Collapse
Affiliation(s)
- Kyle D Weaver
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
| | | | | |
Collapse
|
6
|
Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, Lelouard H, Masciarelli S, Mattioli L, Oliva L, Orsi A, Pasqualetto E, Pierre P, Ruffato E, Tagliavacca L, Sitia R. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006; 25:1104-13. [PMID: 16498407 PMCID: PMC1409720 DOI: 10.1038/sj.emboj.7601009] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2005] [Accepted: 01/26/2006] [Indexed: 11/08/2022] Open
Abstract
After few days of intense immunoglobulin (Ig) secretion, most plasma cells undergo apoptosis, thus ending the humoral immune response. We asked whether intrinsic factors link plasma cell lifespan to Ig secretion. Here we show that in the late phases of plasmacytic differentiation, when antibody production becomes maximal, proteasomal activity decreases. The excessive load for the reduced proteolytic capacity correlates with accumulation of polyubiquitinated proteins, stabilization of endogenous proteasomal substrates (including Xbp1s, IkappaBalpha, and Bax), onset of apoptosis, and sensitization to proteasome inhibitors (PI). These events can be reproduced by expressing Ig-mu chain in nonlymphoid cells. Our results suggest that a developmental program links plasma cell death to protein production, and help explaining the peculiar sensitivity of normal and malignant plasma cells to PI.
Collapse
Affiliation(s)
- Simone Cenci
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Alexandre Mezghrani
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
| | - Paolo Cascio
- Department of Veterinary Morphophysiology, University of Turin, Grugliasco (TO), Italy
| | - Giada Bianchi
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Fulvia Cerruti
- Department of Veterinary Morphophysiology, University of Turin, Grugliasco (TO), Italy
| | - Anna Fra
- Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - Hugues Lelouard
- Centre d'Immunologie de Marseille-Luminy, CNRS-INSERM-Université de la Meditérannée, Marseille, France
| | - Silvia Masciarelli
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Laura Mattioli
- Department of Experimental Medicine, University of Genoa, Genoa, Italy
| | - Laura Oliva
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
| | - Andrea Orsi
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Elena Pasqualetto
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
| | - Philippe Pierre
- Centre d'Immunologie de Marseille-Luminy, CNRS-INSERM-Université de la Meditérannée, Marseille, France
| | - Elena Ruffato
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
| | - Luigina Tagliavacca
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
| | - Roberto Sitia
- Department of Biology and Technology, DiBiT, San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
- Department of Cell & Molecular Biology, Università Vita-Salute San Raffaele, DiBiT-HSR, Via Olgettina 58, Milan 20132, Italy. Tel.: +39 02 2643 4722; Fax: +39 02 2643 4723; E-mail:
| |
Collapse
|
7
|
Abstract
Gingivostomatitis (GS) with various patterns of disease may require antiviral therapy, steroids, laser fulguration, immunomodulation drugs, or nonsteroidal anti-inflammatory drugs. The use of cyclosporine as an immunomodulation drug has long-term benefits in reduction of the immunologic events that contribute to GS. Whole-mouth extraction or partial extraction (premolars and molars), with radiographic conformation that all root remnants have been removed, may be the most viable option in nonresponsive and or intractably painful stomatitis in noncompliant cats or dogs. Oral inflammation subsided after extraction without the need for further medication in approximately 70% of the cats from two studies with previous chronic unrelenting oral disease. The combination of immunomodulation with cyclosporine together with laser resection of proliferative tissue should be recommended if extraction of teeth is not desired. Removal of proliferative oral tissues by lasing (carbon dioxide laser) removes the tissue that maybe producing tissue antigens and the area where bacteria are sequestered. The use of anti-inflammatory medications is recommended in the management of GS. Therapeutic success is achieved when there is elimination of proliferative tissue and inflammation.
Collapse
Affiliation(s)
- Kenneth F Lyon
- Arizona Veterinary Dentistry and Oral Surgery, 86 West Juniper Avenue, Gilbert, AZ 85233, USA.
| |
Collapse
|